Related Experiment Video
Updated: Sep 6, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Tricuspid Valve Percutaneous Therapies
Bhaskar Bhardwaj1, Joaquin E Cigarroa1, Firas Zahr2
1Division of Cardiology, Knight Cardiovascular Institute, OHSU, Portland, OR, United States.
Purpose Of Review:
In this review, we have focused on the currently available transcatheter tricuspid valve therapies, device selection, as well as role and management of tricuspid regurgitation (TR) in the setting of other transcatheter valvular procedures.
Recent Findings:
In this review, we have enlisted the recently finished as well as ongoing trials in the percutaneous tricuspid valve therapies. TR is highly prevalent yet remains underrecognized and is often untreated. TR has traditionally been managed conservatively with medical therapies including diuretics for volume management, whereas surgical therapies are reserved for those undergoing left-sided valvular surgery. Although the transcatheter devices for tricuspid repair and replacement are in clinical trials, the experience to date for their effectiveness and safety has been reassuring.
Related Concept Videos
Mitral Stenosis III: Medical Management
Venous Thrombosis III: Interprofessional Care
Heart Failure VI: Adjunct Therapies
Mitral Regurgitation III: Medical Management
Pericarditis III: Medical Management
Cardiac Catheterization II: Right Heart Catheterization

